CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients
- PMID: 24089443
- DOI: 10.1158/1078-0432.CCR-13-0143
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients
Abstract
Immune checkpoint blockade with monoclonal antibodies directed at the inhibitory immune receptors CTLA-4, PD-1, and PD-L1 has emerged as a successful treatment approach for patients with advanced melanoma. Ipilimumab is the first agent associated with a documented improved overall survival benefit in this patient population. A striking attribute of CTLA-4 blockade is the durability of objective responses, leading to speculation of a possible cure for some patients. Many tumor responses achieved with PD-1 and PD-L1 inhibition were durable in the phase I trials and were seen in a higher proportion of patients with melanoma than typically observed with ipilimumab. Biomarker development to identify the subset of patients with melanoma who will achieve durable clinical benefit with checkpoint blockade is critical; tumor PD-L1 expression has been promising in early studies. The contrast between unprecedented response rates but limited durability of responses achieved with BRAF and MEK inhibition in BRAF(V600)-mutated melanoma and the impressive durability but relatively low rate of response achieved with immune checkpoint blockade is striking. Preclinical data on potential synergies between CTLA-4/PD-1/PD-L1 inhibition and MAPK-targeted therapy is emerging, and combined immune checkpoint blockade and MAPK inhibition are being explored in clinical trials. Other promising approaches to increase the number of patients with melanoma who benefit from durable responses with immune checkpoint blockade include concurrent or sequenced CTLA-4 and PD-1/PD-L1 inhibition and combination with other immunotherapeutic strategies. Clin Cancer Res; 19(19); 5300-9. ©2013 AACR.
Similar articles
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
-
The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.Curr Opin Oncol. 2014 Mar;26(2):204-14. doi: 10.1097/CCO.0000000000000054. Curr Opin Oncol. 2014. PMID: 24424272 Review.
-
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?Curr Opin Immunol. 2015 Apr;33:23-35. doi: 10.1016/j.coi.2015.01.006. Epub 2015 Jan 23. Curr Opin Immunol. 2015. PMID: 25621841 Review.
-
Therapeutic use of anti-CTLA-4 antibodies.Int Immunol. 2015 Jan;27(1):3-10. doi: 10.1093/intimm/dxu076. Epub 2014 Jul 18. Int Immunol. 2015. PMID: 25038057 Review.
-
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Int Immunol. 2015. PMID: 25323844 Review.
Cited by
-
Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment.Front Immunol. 2024 Oct 8;15:1487782. doi: 10.3389/fimmu.2024.1487782. eCollection 2024. Front Immunol. 2024. PMID: 39439803 Free PMC article. Review.
-
Pan-cancer analysis reveals that TK1 promotes tumor progression by mediating cell proliferation and Th2 cell polarization.Cancer Cell Int. 2024 Sep 29;24(1):329. doi: 10.1186/s12935-024-03515-x. Cancer Cell Int. 2024. PMID: 39343871 Free PMC article.
-
Pan-cancer analysis of the role of α2C-adrenergic receptor (ADRA2C) in human tumors and validation in glioblastoma multiforme models.J Cancer. 2024 Sep 9;15(17):5691-5709. doi: 10.7150/jca.98240. eCollection 2024. J Cancer. 2024. PMID: 39308687 Free PMC article.
-
Endoplasmic reticulum-targeted delivery of celastrol and PD-L1 siRNA for reinforcing immunogenic cell death and potentiating cancer immunotherapy.Acta Pharm Sin B. 2024 Aug;14(8):3643-3660. doi: 10.1016/j.apsb.2024.04.010. Epub 2024 Apr 15. Acta Pharm Sin B. 2024. PMID: 39234613 Free PMC article.
-
Comparative Analytical Evaluation of the Proposed Biosimilar FYB206 and its Reference Medicinal Product Keytruda®.Drugs R D. 2024 Sep;24(3):447-464. doi: 10.1007/s40268-024-00485-3. Epub 2024 Sep 4. Drugs R D. 2024. PMID: 39230843 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials